Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial

Researchers from the Hormone Laboratory and international collaborators have recently published findings on MS4A1, HBA2, MT-RNR1, MT-RNR2, EGFL6 and FDCSP expressed in breast tissue from metformin-treated postmenopausal women. Metformin reduces the incidence of breast cancer in patients with obesity and type 2 diabetes, but knowledge about the effect of metformin on breast cancer recurrence is limited. The study was a randomized, double-blind, placebo-controlled phase II study where changes in breast tissue from breast cancer survivors with a BMI > 25 kg/m2 after treatment with metformin were investigated.